CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 66 enrolled
Drug / intervention
VRC-HIVADV014-00-VP +3 morebiological
Likely dose
VRC-HIVADV014-00-VP 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00270218
NCT00270218Phase 1Completed
CompareCT.gov

A Phase I Clinical Trial to Evaluate Immune Response Kinetics and Safety of Two Different Primes, Adenoviral Vector Vaccine (VRC-HIVADV014-00-VP) and DNA Vaccine (VRC-HIVDNA009-00-VP), Each Followed by Adenoviral Vector Boost in Healthy, HIV-1 Uninfected Adults

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Dec 26, 2005·Updated Oct 14, 2021

In Brief

A Phase 1 clinical trial evaluating VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, and 2 other interventions for HIV Infections. Completed, enrolled 66 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine the safety of and immune response to an adenoviral vector HIV vaccine or a DNA HIV vaccine, each followed by an adenoviral vector HIV vaccine boost, in HIV uninfected adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 26, 2005
Enrollment StartFeb 1, 2006
Study CompletionAug 1, 2007
TodayJul 2, 2026
Posted 20.5 years ago

Interventions

VRC-HIVADV014-00-VPbiological

HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid

VRC-HIVDNA009-00-VPbiological

HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid

FFBbiological

Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid

PBSbiological

phosphate buffered saline